GlobalData on MSN18h
GSK eyes up combo approval for previously withdrawn myeloma drug
After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep (belantamab mafodotin) is poised to re-enter the ...
GSK :FDA Accepts Blenrep Combination For Review In Treatment Of Relapsed/Refractory Multiple Myeloma
GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...
The American Journal of Managed Care4d
As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Targeted Oncology5d
Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab
Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...
GlobalData on MSN3d
Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma
The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.
News Medical on MSN11d
Interactive atlas unveils immune changes in multiple myeloma
Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
GSK’s Blenrep Nears FDA Review for Myeloma
GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...
Channel NewsAsia Singapore6d
Recent breakthroughs expand treatment options for multiple myeloma
A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...
MedPage Today on MSN7d
The Evolving Role of MRD in Managing Multiple Myeloma
"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...
Targeted Oncology4d
Exploring the Evolving Role of CAR T-Cell Therapies in Multiple Myeloma
Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.
MedPage Today8d
Assessing Patient Fitness for Transplant in Multiple Myeloma
Opens in a new tab or window While high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT) can deepen ...
Pharmabiz4h
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...